Q1 2025 Organon & Co Earnings Call Transcript
Key Points
- Nexplanon achieved double-digit growth and is expected to surpass $1 billion in revenue for 2025.
- The launch of Vtama in the atopic dermatitis indication has been successful, with expectations to reach $150 million in revenue for the year.
- Organon & Co (OGN) anticipates approximately $200 million in annual savings from restructuring initiatives.
- The company is on track to generate over $900 million of free cash flow before one-time costs in 2025.
- Jada experienced 20% growth in the quarter, with significant adoption in the US and expansion into South Korea and Europe.
- The company faced a 4% constant currency revenue decline in the first quarter year-over-year.
- Pricing pressure was noted, particularly from biosimilars and mature products in the US.
- Mandatory pricing revisions in Japan and competitive price pressures in China impacted the respiratory portfolio.
- The loss of exclusivity for Atozet in Europe posed a significant headwind, contributing to a $200 million revenue impact.
- Adjusted gross margin decreased slightly to 61.7% from 62.1% in the previous year, primarily due to unfavorable pricing.
Hello, and welcome to the Organon first quarter 2025 earnings call and webcast (Operator Instructions)
I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations. You may begin.
Thank you, operator, and good morning, everyone. Thank you for joining Organon's first quarter earnings call. With me today are Kevin Ali, Organon's Chief Executive Officer; and Matt Walsh, our Chief Financial Officer. Juan Camilo Arjona Ferreira, Organon's Head of R&D will also be joining for the Q&A portion of this call. Today, we will be referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events and Presentations section of our Investor Relations website, www.organon.com.
Before we begin, I would like to caution listeners that certain information discussed by management during this conference call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
